Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.955 USD | +0.95% | -7.04% | +147.21% |
May. 28 | Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion | MT |
May. 15 | Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+147.21% | 912M | |
+18.40% | 123B | |
+15.00% | 107B | |
-4.30% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-12.39% | 16.23B | |
+2.51% | 13.43B | |
+24.28% | 11.32B |
- Stock Market
- Equities
- ARQT Stock
- News Arcutis Biotherapeutics, Inc.
- Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $18 From $17, Maintains Buy Rating